Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 339

1.

Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.

Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, Vickers AJ, Sheinfeld J.

J Clin Oncol. 2007 Dec 10;25(35):5603-8.

PMID:
17998544
2.

Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.

Stephenson AJ, Bosl GJ, Motzer RJ, Bajorin DF, Stasi JP, Sheinfeld J.

J Clin Oncol. 2007 Dec 10;25(35):5597-602.

PMID:
18065732
4.

Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M; German Testicular Cancer Study Group..

J Clin Oncol. 2008 Jun 20;26(18):2966-72. doi: 10.1200/JCO.2007.12.0899. Erratum in: J Clin Oncol. 2010 Mar 10;28(8):1439. Dosage error in article text.

PMID:
18458040
5.
6.

Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.

Fléchon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz JP.

BJU Int. 2010 Sep;106(6):779-85. doi: 10.1111/j.1464-410X.2009.09175.x.

7.

Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.

Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL.

Cancer. 2006 Oct 1;107(7):1483-90.

8.

The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.

Dash A, Carver BS, Stasi J, Bajorin DF, Motzer RJ, Bosl GJ, Sheinfeld J.

Cancer. 2008 Feb 15;112(4):800-5. doi: 10.1002/cncr.23233.

10.

Management of patients with low-stage nonseminomatous germ cell testicular cancer.

Stephenson AJ, Sheinfeld J.

Curr Treat Options Oncol. 2005 Sep;6(5):367-77. Review.

PMID:
16107240
11.

Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.

Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J.

J Clin Oncol. 2007 Mar 20;25(9):1033-7.

PMID:
17261854
12.

Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.

Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J.

J Clin Oncol. 2005 Apr 20;23(12):2781-8.

PMID:
15837993
13.

Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.

Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld J.

J Clin Oncol. 2007 Oct 1;25(28):4365-9.

PMID:
17906201
14.

Long-term clinical outcome in patients with stage-I nonseminomatous germ cell cancer. A critical review of own treatment modalities in a retrospective study.

Seseke S, Bierwirth S, Strauss A, Ringert RH, Seseke F.

Int Braz J Urol. 2008 Nov-Dec;34(6):715-22; discussion 723-4.

15.

Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?

Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH.

Cancer. 2007 Sep 15;110(6):1235-40.

16.

Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour.

Masterson TA, Carver BS, Abel EJ, Pettus JA, Bosl GJ, Sheinfeld J.

BJU Int. 2012 Oct;110(7):950-5. doi: 10.1111/j.1464-410X.2012.10947.x.

17.
18.

Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?

Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM.

Cancer. 2006 Oct 1;107(7):1503-10.

19.

Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.

Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J.

J Urol. 2005 Aug;174(2):557-60; discussion 560.

PMID:
16006891
20.

Does the histology of nodal metastasis predict systemic relapse after retroperitoneal lymph node dissection in pathological stage B1 germ cell tumors?

Beck SD, Foster RS, Bihrle R, Cheng L, Donohue JP.

J Urol. 2005 Oct;174(4 Pt 1):1287-90; discussion 1290.

PMID:
16145394
Items per page

Supplemental Content

Support Center